19.05.2022 • NewsBiopharmaGeneral Electric

Cytiva Opens Swiss Cell and Gene Therapy Center

Cytiva, the former biopharma activities of General Electric and now part of Danaher, will open a new manufacturing facility in Grens, Switzerland, on May 31. Operations at the existing site in Eysins will continue through 2023, while full production transfers to the Grens site.

The site will quadruple capacity for manufacturing Sefia, Sepax, and Xuri consumable products with two new ISO class 7 cleanrooms, ensuring that increased future demand can be met. It will also serve as a Center of Excellence for Cytiva’s cell and gene therapy business and will be a base for European customer training programs.

“Our new facility in Grens will enable us to meet global demand for our products, while working with our customers to meet their immediate training and development needs. This facility brings us another step closer to our vision where access to life-changing therapies transforms human health,” commented Catarina Flyborg, vice president, cell and gene therapy.

In March, Cytiva announced the opening of a new facility in Cardiff, Wales, for making single-use products used in the development and production of biopharmaceuticals, such as Covid-19 vaccines.

A first ISO 7 class cleanroom in Cardiff is already completed, with another five due to be finished later this year. When complete, the site will help increase the company’s global manufacturing capacity for single-use products by 20%.

Cytiva said the expansion will help the needs of the UK’s rapidly growing life sciences sector. According to the company, $6 billion was raised last year in public and private financing by UK biotech companies, a 60% jump on 2020.

Author: Elaine Burridge, Freelance Journalist

© 2022 Cytiva
© 2022 Cytiva

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.